- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01375166
Coupling of Neural Activity and Retinal Blood Flow in Diabetes
The prevalence of diabetes is increasing and the management of the disease is nowadays considered a major challenge. Affected patients have increased mortality and morbidity as well as a significant drop in the quality of life. The complications of diabetes can be classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular (e.g. cardiovascular or cerebrovascular).
Several large-scale epidemiologic studies indicating that wider retinal venous caliber is strongly associated with the fasting glucose level as well as with diabetes. Another retinal vascular abnormality that is associated with diabetes is an abnormal retinal vascular response to flicker stimulation. Retinal vessel dilatation in response to stimulation with diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means that increased activity of neurons is associated with an increased retinal metabolism. This leads to a release of endogenous vasodilator substances and increased blood flow. However, previous studies were limited by the fact that retinal vessel diameters and blood flow were not measured simultaneously.
The present study aims to investigate whether the response of retinal vessel diameters and blood flow velocities to flicker stimulation is altered in patients with diabetes. Both parameters will be measured in real time using Fourier Domain Doppler OCT.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women aged over 18 years, nonsmokers
- Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant
- normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters
- inclusion criterion of patients is type I diabetes with non or mild non-proliferative retinopathy
Exclusion criteria
Any of the following will exclude a healthy subject from the study:
- Regular use of vasoactive drugs
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- History or presence of any ocular pathology
- History or family history of epilepsy
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- Pregnancy
Any of the following will exclude a subject with diabetes from the study:
- Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)
- History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy
- Best corrected visual acuity <0.8
- Previous laser photocoagulation treatment
- Systemic hypertension defined as systolic blood pressure >150mmHg, diastolic blood pressure >90mmHg
- History or family history of epilepsy
- Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- Blood donation during the previous 3 weeks
- Pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Diabetic retinopathy
Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
|
|
healthy
healthy control subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Retinal vessel diameters
Time Frame: 18 months
|
18 months
|
|
Retinal blood flow velocities
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPHT-070111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
Sara A BelalRecruitingDiabetes (DM) | Diabetic Retinopathy (DR) | Retinopathy, Diabetic | Diabetic Retinopathy Associated With Type 2 Diabetes MellitusEgypt
-
Bojie HuCompletedProliferative Diabetic RetinopathyChina
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Da Nang Family General HospitalRecruiting
-
Federico II UniversityCompletedDiabetic Retinopathy, DRItaly
-
Osijek University HospitalRecruitingDiabetic Macular Edema (DME) | Diabetic Retinopathy (DR)Croatia
-
Ain Shams UniversityNational Institute of Diabetes and Endocrinology, EgyptRecruitingDiabetic Retinopathy (DR)Egypt
-
Centervue SpANot yet recruitingDiabetic Retinopathy (DR)
-
University of Illinois at ChicagoNational Eye Institute (NEI)RecruitingDiabetic Retinopathy (DR)United States